GoldenMed BioTechnology Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2014
NCT02289300
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

dcb-bo1202 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Fibrosis (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Liver Cirrhosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1